{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2010_0009920_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"111-542-664-392-395"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8902,"type":"PATENT","title":"University of Tokyo Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":20983,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8217,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners = \"Univ Tokyo\", \"Univ Tokyo NOT metropolitan\", \"Tokyo Univ\",\"University of Tokyo NOT metropolitan\", \"Tokyo Univ\".
Select more for logical variants
Add to collection
Total patent: 13934
Search applicants and owners = \"Univ Tokyo\", \"Univ Tokyo NOT metropolitan\", \"Tokyo Univ\",\"University of Tokyo NOT metropolitan\", \"Tokyo Univ\".
Select more for logical variants
Add to collection
Total patent: 13934
a. detecting either or both of a TTK expression level and a phosphorylation level of EGFR in a specimen collected from a subject whose lung cancer prognosis is to be assessed, and\n
b. indicating a poor prognosis when an elevated either or both of TTK expression level and a phosphorylation level of EGFR, as compared to a control level, is detected."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the TTK expression level is detected by any one of the methods selected from the group consisting of:\n
(a) detecting the presence of an mRNA encoding the amino acid sequence of SEQ ID NO: 2,\n
(b) detecting the presence of a protein comprising the amino acid sequence of SEQ ID NO: 2, and\n
(c) detecting a biological activity of a protein comprising the amino acid sequence of SEQ ID NO: 2."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the biological activity of (c) is a kinase activity for EGFR."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the phosphorylation level of EGFR is detected at tyrosine of 992 amino acid residue or serine of 967 amino acid residue in SEQ ID NO: 42."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A kit for assessing lung cancer prognosis, wherein the kit comprises any one component selected from the group consisting of:\n
(a) a reagent for detecting an mRNA encoding the amino acid sequence of SEQ ID NO: 2,\n
(b) a reagent for detecting a protein comprising the amino acid sequence of SEQ ID NO: 2 or tyrosine of 992 amino acid residue or serine of 967 amino acid residue in SEQ ID NO: 42, and\n
(c) a reagent for detecting a biological activity of a protein comprising the amino acid sequence of SEQ ID NO: 2."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A method of diagnosing lung cancer or a predisposition for developing lung cancer in a subject, comprising determining TTK expression level or phosphorylation level of EGFR in a biological sample from a subject, wherein an increase of said expression level or pohsphorylation level in said sample as compared to a normal control level of said gene indicates that said subject suffers from or is at risk of developing lung cancer."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said sample expression level is at least 10% greater than said normal control level."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein TTK expression level is determined by a method selected from the group consisting of:\n
a) detecting an mRNA encoding the amino acid sequence of SEQ ID NO: 2,\n
b) detecting a protein comprising the amino acid sequence of SEQ ID NO: 2, and\n
c) detecting a biological activity of a protein comprising the amino acid sequence of SEQ ID NO: 2."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8, wherein the biological activity is a kinase activity for EGFR."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the phosphorylation level of EGFR is detected at tyrosine of 992 amino acid residue or serine of 967 amino acid residue in SEQ ID NO: 42."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said subject-derived biological sample comprises an epithelial cell."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said biological sample comprises a lung cell."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6 wherein said biological sample comprises an epithelial cell from a lung tissue."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A kit for diagnosing lung cancer or a predisposition for developing lung cancer m a subject, wherein the kit comprises a reagent for detecting the kinase activity of TTK for EGFR."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The kit of claim 14, wherein the kinase activity of TTK for EGFR is an EGF-independent phosphorylation of EGFR by TTK."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method of measuring a kinase activity of TTK for EGFR, said method comprising the steps of:\n
a. incubating EGFR or functional equivalent thereof and TTK under conditions suitable for the EGFR phosphorylation by TTK, wherein the TTK is selected from the group consisting of:\n\ni. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 (TTK);\nii. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are substituted, deleted, or inserted, provided the resulting polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\niii. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, provided the resulting polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\n
b. detecting a phospho-EGFR level; and\n
c. measuring the kinase activity of TTK by correlating the phosphor-EGFR level detected in step (b)."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein the functional equivalent of EGFR is a fragment comprising amino acid sequence of SEQ ID NO: 43"],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein the phospho-EGFR level is detected at tyrosine of 992 amino acid residue or serine of 967 amino acid residue in SEQ ID NO: 42."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying an agent that modulates a kinase activity of TTK for EGFR, said method comprising the steps of:\n
a. incubating EGFR or functional equivalent thereof and TTK in the presence of a test compound under conditions suitable for the phosphorylation of EGFR by TTK, wherein the TTK is a polypeptide selected from the group consisting of:\n\ni. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 (TTK);\nii. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are substituted, deleted, or inserted, provided the resulting polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\niii. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, provided the resulting polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\n
b. detecting a phospho-EGFR level; and\n
c. comparing the phospho-EGFR level to a control level, wherein an increase or decrease in the phospho-EGFR level as compared to said control level indicates that the test compound modulates the kinase activity of TTK for EGFR."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the functional equivalent of EGFR is a fragment comprising amino acid sequence of SEQ ID NO: 43"],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the phospho-EGFR level is detected at tyrosine of 992 amino acid residue or serine of 967 amino acid residue in SEQ ID NO: 42."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening for a compound for treating and/or preventing lung cancer, said method comprising the steps of:\n
a. incubating EGFR or functional equivalent thereof and TTK in the presence of a test compound under conditions suitable for the phosphorylation of EGFR by TTK, wherein the TTK is a polypeptide selected from the group consisting of:\n\ni. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 (TTK);\nii. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are substituted, deleted, or inserted, provided said polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\niii. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, provided the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\n
b. detecting a phospho-EGFR level; and\n
c. selecting a compound that decreases the phospho-EGFR level as compared to a control level."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein or functional equivalent of EGFR is a fragment comprising amino acid sequence of SEQ ID NO: 43."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the phospho-EGFR level is detected at tyrosine of 992 amino acid residue or serine of 967 amino acid residue in SEQ ID NO: 42."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A kit for detecting the ability of a test compound to modulate kinase activity of TTK for EGFR, said kit comprising the components of:\n
A) a polypeptide selected from the group consisting of:\n\ni. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 (TTK);\nii. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are substituted, deleted, or inserted, provided the resulting polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\niii. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, provided the resulting polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\n
B) EGFR or EGFR fragment comprising the amino acid sequence of SEQ ID NO: 43; and\n
C) a reagent for detecting a phospho-EGFR."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A kit for detecting for the ability of a test compound to modulate kinase activity of TTK for EGFR, said kit comprising the components of:\n
A) a cell expressing EGFR or EGFR fragment comprising the amino acid sequence of SEQ ID NO: 43 and a polypeptide selected from the group consisting of:\n\ni. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 (TTK);\nii. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are substituted, deleted, or inserted, provided the resulting polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;\niii. a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, provided the resulting polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2; and\n
B) a reagent for detecting a phospho-EGFR."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method of predicting a metastasis of lung cancer, said method comprising the steps of:\n
a. detecting one or more mutations of TTK at kinase domain,\n
b. indicating a high risk of metastasis of lung cancer when a mutation is detected."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein one or more mutations of TTK at kinase domain are selected from the group consisted of Valine to Phenylalanine at codon 610 (V610F), Glutamine to Histidine at codon 753 (Q753H) and Tyrosine to Cysteine at codon 574 (Y574C) of SEQ ID NO: 2."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["A method for detecting one or more mutation of TTK, wherein the mutation is at least one mutation selected from the group consisted of Valine to Phenylalanine at codon 610 (V610F), Glutamine to Histidine at codon 753 (Q753H) and Tyrosine to Cysteine at codon 574 (Y574C) of SEQ ID NO: 2, the method comprises steps of:\n
a) contacting a subject polypeptide or cDNA encoding them with binding agent recognizing any one of the mutation of the polypeptide or cDNA encoding them,\n
b) detecting the binding agent with the polypeptide or cDNA encoding them, and\n
c) showing the mutation of TTK when the binding of the agent of step b) is detected."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 29, wherein the binding agent is an antibody that binds to polypeptide comprising at least one mutation selected from the group consisted of Valine to Phenylalanine at codon 610 (V610F), Glutamine to Histidine at codon 753 (Q753H) and Tyrosine to Cysteine at codon 574 (Y574C) of SEQ ID NO: 2, and substantially does not binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["A reagent for detecting one or more mutation of TTK, wherein the mutation is at least one mutation selected from the group consisted of Valine to Phenylalanine at codon 610 (V610F), Glutamine to Histidine at codon 753 (Q753H) and Tyrosine to Cysteine at codon 574 (Y574C) of SEQ ID NO: 2, wherein the reagent comprises a binding agent recognizing any one of the mutation of the polypeptide or cDNA encoding them."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The reagent of claim 31, wherein the binding agent is an antibody that binds to polypeptide comprising at least one mutation selected from the group consisted of Valine to Phenylalanine at codon 610 (V610F), Glutamine to Histidine at codon 753 (Q753H) and Tyrosine to Cysteine at codon 574 (Y574C) of SEQ ID NO: 2, and substantially does not binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["An isolated polynucleotide comprising a mutated nucleotide sequence of SEQ ID NO: 1, wherein the nucleotide sequence comprises one or more mutations selected from the group consisting of A1870G (for V610F), G1977T (for Q753H) and G2408C (for Y574C), or fragment thereof comprising the one or more mutations."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["An isolated polypeptide comprising a mutated amino acid sequence of SEQ ID NO: 2, wherein the amino acid sequence comprises one or more mutations selected from the group consisting of V610F, Q753H and for Y574C, or fragment thereof comprising the one or more mutations."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating or preventing lung cancer comprising the step of administering at least any one polypeptide selected from the group consisting of;\n
(a) a polypeptide comprising ISSILEKGERLPQPPICTI (SEQ ID NO: 44), DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) or FRELIIEFSKMARDPQRYL (SEQ ID NO: 46), and\n
(b) a polypeptide functionally equivalent to the polypeptide selected from the group consisting of ISSILEKGERLPQPPICTI (SEQ ID NO: 44), DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) and FRELIIEFSKMARDPQRYL (SEQ ID NO: 46),\n
wherein the polypeptide lacks the biological function of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2,\n
or a polynucleotide encoding the polypeptide selected from the polypeptide of (a) and (b)."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["A composition for treating or preventing lung cancer comprising a pharmaceutically effective amount of at least any one polypeptide selected from the group consisting of;\n
(a) a polypeptide comprising ISSILEKGERLPQPPICTI (SEQ ID NO: 44), DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) or FRELIIEFSKMARDPQRYL (SEQ ID NO: 46), and\n
(b) a polypeptide functionally equivalent to the polypeptide selected from the group consisting of ISSILEKGERLPQPPICTI (SEQ ID NO: 44), DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) and FRELIIEFSKMARDPQRYL (SEQ ID NO: 46),\n
wherein the polypeptide lacks the biological function of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2\n
or a polynucleotide encoding the polypeptide selected from the polypeptide of (a) and (b) and a pharmaceutically acceptable carrier."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["A polypeptide selected from the group consisting of;\n
(a) a polypeptide comprising ISSILEKGERLPQPPICTI (SEQ ID NO: 44), DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) or FRELIIEFSKMARDPQRYL (SEQ ID NO: 46), and\n
(b) a polypeptide having an amino acid sequence of a polypeptide functionally equivalent to the polypeptide selected from the group consisting of ISSILEKGERLPQPPICTI (SEQ ID NO: 44), DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) and FRELIIEFSKMARDPQRYL (SEQ ID NO: 46),\n
wherein the polypeptide lacks the biological function of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["A polynucleotide encoding the polypeptide of claim 37."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of the claim 37, wherein the biological function is cell proliferation activity."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of claim 37, wherein the polypeptide consists of 19 to 57 residues."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of claim 37, wherein the polypeptide is modified with a cell-membrane permeable substance,"],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of claim 41, which has the following general formula:\n
\n\n[R]−[D];\n\n
wherein [R] represents the cell-membrane permeable substance; and [D] represents the amino acid sequence of a fragment sequence which comprises ISSILEKGERLPQPPICTI (SEQ ID NO: 44) or DVYMIMVKCWMIDADSRPK (SEQ ID NO: 45) or FRELIIEFSKMARDPQRYL (SEQ ID NO: 46); or the amino acid sequence of a polypeptide functionally equivalent to the polypeptide comprising said fragment sequence, wherein the polypeptide lacks the biological function of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, wherein [R] and [D] can be linked directly or indirectly through a linker comprising amino acid sequences consisting of GGG."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of claim 42, wherein the cell-membrane permeable substance is any one selected from the group consisting of:\n
poly-arginine;\n\nSEQ ID NO: 47Tat/RKKRRQRRR/; SEQ ID NO: 48Penetratin/RQIKIWFQNRRMKWKK/; SEQ ID NO: 49Buforin II/TRSSRAGLQFPVGRVHRLLRK/; SEQ ID NO: 50Transportan/GWTLNSAGYLLGKINLKALAALAKKIL/; SEQ ID NO: 51MAP (model amphipathic peptide)/KLALKLALKALKAALKLA/; SEQ ID NO: 52K-FGF/AAVALLPAVLLALLAP/; SEQ ID NO: 53Ku70/VPMLK/ SEQ ID NO: 61Ku70/PMLKE/; SEQ ID NO: 54Prion/MANLGYWLLALFVTMWTDVGLCKKRPKP/; SEQ ID NO: 55pVEC/LLIILRRRIRKQAHAHSK/; SEQ ID NO: 56Pep-1/KETWWETWWTEWSQPKKKRKV/; SEQ ID NO: 57SynB1/RGGRLSYSRRRFSTSTGR/; SEQ ID NO: 58Pep-7/SDLWEMMMVSLACQY/;and SEQ ID NO: 59HN-1/TSPLNIHNGQKL/."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The polypeptide of claim 43, wherein the poly-arginine is Arg 11 (RRRRRRRRRRR/SEQ ID NO: 60)."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating or preventing lung cancer comprising administering to subject a composition comprising a double-stranded molecule which reduces TTK (SEQ ID NO: 1) or EGFR (SEQ ID NO: 3) gene expression, wherein the double-stranded molecule comprises a sense nucleic acid and an anti-sense nucleic acid, wherein the sense nucleic acid comprises a ribonucleotide sequence corresponding to a sequence of SEQ ID NO: 62 or 63 as the target sequence."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 45, wherein said composition comprises a transfection-enhancing agent."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["A composition for treating or preventing lung cancer comprising a pharmaceutically effective amount of a double-stranded molecule which reduces TTK (SEQ ID NO: 1) or EGFR (SEQ ID NO: 3) gene expression, and a pharmaceutically acceptable carrier, wherein the double-stranded molecule comprises a sense nucleic acid and an anti-sense nucleic acid, wherein the sense nucleic acid comprises a ribonucleotide sequence corresponding to a sequence of SEQ ID NO: 62 or 63 as the target sequence."],"number":47,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}